Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Panel OKs Japan’s First Abortion Pill, but Upper Organ to Review It Again after Public Comments
January 30, 2023
- Japan Should Stick to Current COVID Vaccination System: Panel Members
January 27, 2023
- Experts Doubt Necessity of Policy Intervention for LLP-Dependent Companies
January 27, 2023
- Expert Panel Member Alarmed by Stagnation of Biosimilar Business in Japan
January 27, 2023
- MHLW to Support Development of Drugs and Vaccines for Infectious Diseases from PIII Onwards: Counsellor
January 26, 2023
- Chuikyo Begins Xocova Price Debate under Mega Seller Rule, Weighs Quicker Re-Pricing
January 26, 2023
- Japan to Revise Revlimid Risk Management Rule in June; February Generic Approval Eyed
January 25, 2023
- MHLW Warns of Inadvertent Xocova Use in Pregnant Women after 2 Cases Reported
January 25, 2023
- MHLW Details Plan to Ensure Stable Supplies of β-Lactam Antibiotics
January 24, 2023
- PM Kishida Hails Lecanemab as World’s First Innovative AD Drug Originating from Japan
January 24, 2023
- MHLW Panel OKs 62 More Health Damage Claims for COVID-19 Vaccines
January 24, 2023
- Xocova Might Trigger Mega Seller Price Control Rule for First Time
January 24, 2023
- Setting “Presumed Efficacy” Criteria Would Be Difficult; Xocova Decision Reasonable: PMDA Chief
January 23, 2023
- First Abortion Pill Candidate in Japan Up for Panel Review on Jan. 27
January 23, 2023
- No Major Safety Concerns for COVID-19 Vaccines in Japan: MHLW Panels
January 23, 2023
- PMDA Reviewing Safety Risks for GLP-1 Agents
January 23, 2023
- Label Revision Ordered for Acetaminophen to Add Drug-Induced Hypersensitivity Syndrome as ADR
January 19, 2023
- Label Expansions for Nubeqa, Rinvoq, Imbruvica on PAFSC Agenda for Feb. 1
January 19, 2023
- Chuikyo’s Drug Pricing Debate Slated to Begin in May after Expert Panel Proposal
January 19, 2023
- Emgality, Revestive, Veklury Brace for Price Cuts under CEA Scheme
January 19, 2023
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…